Clinical Trials
12 trialsNCT07627698 2026-06-04
DUET-MEL
Beijing Biotech
Phase 1/2 Recruiting
NCT03941379 2026-05-22
A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma
Aura Biosciences
Active not recruiting
NCT03686124 2026-05-13
ACTengine
Immatics US, Inc.
Phase 1/2 Recruiting
NCT04855435 2026-05-12
Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
MonTa Biosciences ApS
Phase 1 Recruiting
NCT07015190 2026-05-06
Neoadjuvant Darovasertib in Primary Uveal Melanoma
IDEAYA Biosciences
Phase 3 Recruiting
NCT05496686 2026-04-03
Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
Modulation Therapeutics, Inc.
Phase 1 Active not recruiting
NCT06581406 2026-04-02
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Replimune, Inc.
Phase 2/3 Recruiting
NCT04328844 2026-03-30
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
Phase 1 Active not recruiting
NCT03070392 2026-03-17
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Immunocore Ltd
Phase 2 Completed
NCT05907954 2026-03-16
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
IDEAYA Biosciences
Phase 2 Active not recruiting
NCT07076550 2026-03-16
A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma
Alpha-9 Oncology USA Inc.
Phase 1 Recruiting
NCT05199584 2026-03-05
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Phase 2 Completed